靶向GPC3的CAR-T疗法：开创肝癌治疗新纪元

肝细胞癌（Hepatocellular Carcinoma，HCC）是全球常见的恶性肿瘤之一，由于其早期症状不明显，常常在晚期才被诊断，给治疗带来了巨大的挑战。随着精准治疗和免疫疗法的快速发展，CAR-T细胞疗法作为一种新兴的免疫治疗手段，在肝癌治疗中展现出了巨大的潜力，特别是针对GPC3（肝细胞癌特异性抗原）的CAR-T疗法，已经取得了显著的研究进展。通过改造T细胞使其能够识别并攻击肝细胞癌中的GPC3抗原，研究人员期望能够有效突破传统治疗方法的局限，带来更好的治疗效果，为肝癌患者提供新的希望。

GPC3（Glypican-3）是一种细胞表面糖蛋白，主要表达于多种肿瘤细胞表面，尤其在肝细胞癌中具有高度特异性。GPC3的高表达与肝癌的发生、发展密切相关，它通过调控细胞生长、抑制凋亡及促进肿瘤细胞的迁移和浸润，起到促进肿瘤发展的作用。更重要的是，GPC3在健康肝细胞中的表达较少，因此它成为了肝细胞癌治疗的理想靶点。通过靶向GPC3，CAR-T细胞疗法有望精准识别和攻击肝癌细胞，从而提高治疗效果。

• 高活性GPC3蛋白，经FACS、ELISA等多种形式验证

5e5 of anti-GPC3 CAR-293 cells were stained with 100 μL of 1:25 dilution (4 μL stock solution in 100 μL FACS buffer) of APC-Labeled Human Glypican 3, His Tag (Cat. No. GP3-HA2H9) and negative control protein respectively. APC signal was used to evaluate the binding activity (QC tested).

2e5 of Anti-Glypican 3 CAR-293 cells were stained with 100 μL of 3 μg/mL of FITC-Labeled Human Glypican 3, Fc Tag (Cat. No. GP3-HF258) and negative control protein respectively. FITC signal was used to evaluate the binding activity (QC tested).

The purity of Human Glypican 3 (359-559) Protein, His Tag (Cat. No. GP3-H52H5) is more than 90% and the molecular weight of this protein is around 24-38 kDa verified by SEC-MALS.

• 高特异性GPC3蛋白，经未转染CAR的PBMC非特异性验证

5e5 of PBMCs were stained with APC-Labeled Human Glypican 3 Protein, His Tag (Cat. No. GP3-HA2H7) and anti-CD3 antibody, washed and then analyzed with FACS. FITC signal was used to evaluate the expression of CD3+ T cells in PBMCs, and APC signal was used to evaluate the non-specific binding activity to PBMCs (QC tested).

>>>专为CAR-T细胞质控和临床样本分析检测而设计的靶点蛋白

参考文献

1.Glypican-3: A Novel and Promising Target for the Treatment of Hepatocellular Carcinoma.

2.Glypican 3-Targeted Therapy in Hepatocellular Carcinoma

3.Glypican-3: A New Target for Diagnosis and Treatment of Hepatocellular Carcinoma.